These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 17606790)

  • 1. Zebra lines of pamidronate therapy in children.
    Al Muderis M; Azzopardi T; Cundy P
    J Bone Joint Surg Am; 2007 Jul; 89(7):1511-6. PubMed ID: 17606790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Images in clinical medicine. Radiographic zebra lines from cyclical pamidronate therapy.
    Sarraf KM
    N Engl J Med; 2011 Jul; 365(3):e5. PubMed ID: 21774705
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta.
    Rauch F; Cornibert S; Cheung M; Glorieux FH
    Bone; 2007 Apr; 40(4):821-7. PubMed ID: 17223617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclical intravenous pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta.
    Land C; Rauch F; Glorieux FH
    J Bone Miner Res; 2006 Mar; 21(3):374-9. PubMed ID: 16491284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V.
    Zeitlin L; Rauch F; Travers R; Munns C; Glorieux FH
    Bone; 2006 Jan; 38(1):13-20. PubMed ID: 16162424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Torg-Winchester syndrome: lack of efficacy of pamidronate therapy.
    Phadke SR; Ramirez M; DiFeo A; Martignetti JA; Girisha KM
    Clin Dysmorphol; 2007 Apr; 16(2):95-100. PubMed ID: 17351352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiographic features of bisphosphonate therapy in pediatric patients.
    Grissom LE; Harcke HT
    Pediatr Radiol; 2003 Apr; 33(4):226-9. PubMed ID: 12709749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
    Glorieux FH; Bishop NJ; Plotkin H; Chabot G; Lanoue G; Travers R
    N Engl J Med; 1998 Oct; 339(14):947-52. PubMed ID: 9753709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful results of pamidronate treatment in children with osteogenesis imperfecta with emphasis on the interpretation of bone mineral density for local standards.
    Poyrazoglu S; Gunoz H; Darendeliler F; Bas F; Tutunculer F; Eryilmaz SK; Bundak R; Saka N
    J Pediatr Orthop; 2008 Jun; 28(4):483-7. PubMed ID: 18520289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteogenesis imperfecta: anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy.
    Vallo A; Rodriguez-Leyva F; Rodríguez Soriano J
    Acta Paediatr; 2006 Mar; 95(3):332-9. PubMed ID: 16497645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose intravenous pamidronate treatment in osteogenesis imperfecta.
    Gökşen D; Coker M; Darcan S; Köse T; Kara S
    Turk J Pediatr; 2006; 48(2):124-9. PubMed ID: 16848111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy.
    Rauch F; Travers R; Glorieux FH
    J Clin Endocrinol Metab; 2006 Feb; 91(2):511-6. PubMed ID: 16291701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
    Land C; Rauch F; Travers R; Glorieux FH
    Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta.
    Weber M; Roschger P; Fratzl-Zelman N; Schöberl T; Rauch F; Glorieux FH; Fratzl P; Klaushofer K
    Bone; 2006 Sep; 39(3):616-22. PubMed ID: 16644299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pamidronate treatment and posttreatment bone density in children with spastic quadriplegic cerebral palsy.
    Bachrach SJ; Kecskemethy HH; Harcke HT; Lark RK; Miller F; Henderson RC
    J Clin Densitom; 2006; 9(2):167-74. PubMed ID: 16785077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonate-induced zebra lines in fibrous dysplasia of bone: histo-radiographic correlation in a case of McCune-Albright syndrome.
    Corsi A; Ippolito E; Robey PG; Riminucci M; Boyde A
    Skeletal Radiol; 2017 Oct; 46(10):1435-1439. PubMed ID: 28660402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment.
    Chapurlat RD; Hugueny P; Delmas PD; Meunier PJ
    Bone; 2004 Jul; 35(1):235-42. PubMed ID: 15207763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Large osteoclasts in pediatric osteogenesis imperfecta patients receiving intravenous pamidronate.
    Cheung MS; Glorieux FH; Rauch F
    J Bone Miner Res; 2009 Apr; 24(4):669-74. PubMed ID: 19063679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.
    Letocha AD; Cintas HL; Troendle JF; Reynolds JC; Cann CE; Chernoff EJ; Hill SC; Gerber LH; Marini JC
    J Bone Miner Res; 2005 Jun; 20(6):977-86. PubMed ID: 15883638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiographic long bone appearance in a child administered cyclical pamidronate.
    Davies JH; Gregory JW
    Arch Dis Child; 2003 Oct; 88(10):854. PubMed ID: 14500300
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.